NCT03816345: Nivolumab in Treating Patients With Autoimmune Disorders or Advanced, Metastatic, or Unresectable Cancer

NCT03816345
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: MSI-H
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Eligible tumor types include solid tumors in which there is known evidence of clinical activity for single agent PD-1 or PD-L1 antibodies; Patients with new or progressive brain metastases (active brain metastases) or leptomeningeal disease are eligible as long as specific CNS treatment is not needed for at least 4 weeks – see trial for details
Exclusions: Patients with prior therapy with an anti-PD-1 or anti-PD-L1
https://ClinicalTrials.gov/show/NCT03816345

Comments are closed.

Up ↑